New research suggests that patients who come off popular weight-loss injections like semaglutide or tirzepatide can put back on reduced body mass at a significantly accelerated pace than those who stop conventional lifestyle plans.
Research printed in a leading health publication shows that while obese individuals often shed a large proportion of their total mass while on the medication, the mass returns at an estimated rate of nearly a kilo each month once they quit.
"People purchasing these drugs should be aware of the danger of fast weight regain when the therapy is stopped," stated lead investigator Dr. Susan Jebb.
Such speed of regain suggests a return to starting mass within about one and a half years.
Analyzing Therapies
The research, which looked at dozens of studies involving thousands of patients, contrasted the outcomes of GLP-1 agonists with conventional dieting.
Researchers point out that individuals who lose weight through lifestyle changes alone typically experience a more gradual creep back—approximately 100 grams monthly—once they finish.
Explaining the Quick Rebound
Nutrition scientists suggest the mode of action of the drugs is key to understanding the accelerated weight return.
GLP-1 drugs imitate a natural hormone called GLP-1, which moderates appetite.
"Artificially providing GLP-1 levels several times higher than normal might result in the system to produce less of its endogenous hormone, and could lessen sensitivity to its actions," explained Dr. Adam Collins, a nutrition researcher.
"Discontinuation of this medication results in hunger is unsuppressed, making binge eating much more probable."
A Lifelong Disease?
Medical guidelines suggest the jabs for people with obesity-related health risks, accompanied by recommended lifestyle changes.
Many experts argue that, due to the high risk of relapse, the therapy might need to be ongoing.
This view is echoed by drug manufacturers, who note that the findings "highlight the persistent nature of excess weight," akin to managing conditions like hypertension.
Patient Accounts
Individuals who have come off the medication explain a sudden return of hunger.
"It felt as if something that goes on and I was suddenly ravenous," said an individual.
The struggle is compounded if individuals have not adopted lasting dietary or behavioural modifications during therapy.
Widespread Interest
Survey data suggest that a significant number of people in the UK have tried weight-loss jabs in the last 12 months, with desire being substantial.
- Adoption is more common among females than males.
- The middle-aged age group shows the highest level of interest.
- Many obtain the medications through private prescriptions rather than the NHS.
Finally, experts stress that while GLP-1 drugs are potent tools for shedding pounds, they are not a standalone fix and maintained weight loss relies on combined behavioural changes.
